• 10
Reading Time: 6 minutes

The plantar fat pad is the foot’s built-in shock absorber. Beneath the heel and the metatarsal heads, compartments of specialised fat bound by fibrous septae spread load and cushion bone with every step. In many people with diabetes this cushion thins, hardens, or migrates forward, leaving bony prominences with little soft tissue between them and the ground. Because elevated plantar pressure combined with neuropathy is a central pathway to ulceration, interest has grown in whether restoring lost padding could reduce pressure and ulcer risk. This article reviews the evidence on plantar fat pad augmentation, focusing on autologous fat grafting.

Why Fat Pad Loss Matters in the Diabetic Foot

The International Working Group on the Diabetic Foot (IWGDF) identifies elevated plantar pressure as a key modifiable factor in both first-time and recurrent plantar ulcers, and its 2023 prevention guideline centres on reducing that pressure through footwear, offloading, and, in selected cases, surgery (Bus et al., 2024). Fat pad atrophy contributes to this problem. Thinner tissue under the metatarsal heads concentrates load on a smaller area, and glycation of collagen in diabetes stiffens the remaining tissue so that it absorbs less energy. Clawing of the lesser toes, common with motor neuropathy, can also pull the submetatarsal fat pad distally, uncovering the metatarsal heads.

Conventional management relies on external cushioning: custom insoles, extra-depth footwear, and rocker soles. These approaches work only when worn, which is why clinicians and researchers have explored internal, tissue-based alternatives.

Early Approaches: Injectable Silicone and Fillers

Before fat grafting, liquid silicone injection was studied as a way to thicken plantar tissue. Earlier work summarised by Gusenoff and Gusenoff (2016) showed that silicone could increase tissue thickness and reduce plantar pressure for about a year, but that the cushioning effect diminished by two years, with pressures rising again. Silicone can also migrate, may carry infection risk in people with diabetes, and is difficult to remove. Commercial hyaluronic acid and poly-L-lactic acid fillers have been suggested as alternatives, but the same authors noted the absence of safety data for these products in the weight-bearing foot, along with concerns about dispersal during walking, granuloma formation, and cost.

Autologous Fat Grafting: The Randomised Evidence

Autologous fat grafting harvests a small volume of the patient’s own fat, typically from the abdomen or thigh, purifies it, and injects it in small aliquots beneath the atrophic plantar areas. Being the patient’s own tissue, the graft carries no rejection risk.

The most rigorous study of plantar fat grafting for fat pad atrophy remains a prospective randomised trial by Gusenoff and colleagues published in Plastic and Reconstructive Surgery (2016). Twenty-five patients were randomised to immediate fat grafting (mean 4.8 cc per foot) or to one year of conservative care. At one year, the grafted group reported significant improvements in foot function, pain, and work and leisure activity. Plantar tissue thickness was maintained in the grafted group, whereas the control group showed a significant decrease in tissue thickness under the third metatarsal and a significant increase in foot pressure. Between groups, the control patients had significantly higher foot pressures and forces at one year. The authors concluded that fat grafting improved pain and disability and protected against worsening pressures, while noting that long-term durability was not yet established. Reported complications in this group’s experience were minor, chiefly transient lumpiness and short-lived heel discomfort.

It is important to note that this trial was small and did not enrol only people with diabetes, and it did not measure ulcer incidence. A trial registered specifically for diabetic fat pad atrophy (NCT02074683) reflects ongoing efforts to answer that question directly.

Fat-Derived Therapies for Existing Ulcers

A related but separate line of research uses fat grafts or adipose-derived products to heal established wounds rather than to prevent them. A 2025 systematic review in Frontiers in Surgery (Sbitan et al.) identified 16 randomised trials of adipose-derived therapies across wounds, ulcers, and scars. Several trials reported faster or more complete healing and low rates of side effects, but the authors judged the evidence preliminary because many positive trials carried a high or unclear risk of bias, and the heterogeneity of studies prevented meta-analysis. In diabetic foot ulcers specifically, a small feasibility randomised trial by Grant and colleagues (2021) compared fat grafting, fat grafting with platelet-rich plasma, and usual care in 16 patients, an important step toward a definitive trial rather than proof of benefit (cited in Ouyang et al., 2023). A 2025 systematic review in the Journal of Foot and Ankle Research (Ashmore et al.) has examined submetatarsal fat pad augmentation specifically for the treatment and prevention of diabetes-related foot ulceration, reflecting the growing attention to this approach.

Clinical Summary

Plantar fat pad atrophy raises plantar pressure and contributes to ulcer risk in the diabetic foot. Injectable silicone produced only temporary benefit with notable drawbacks, and commercial fillers lack safety data in the foot. Autologous fat grafting has the strongest supporting evidence of the injectable options, with one randomised trial showing improved pain and function and protection against rising plantar pressure over one year, and a favourable short-term safety profile. However, the evidence base is small, follow-up is short, and no adequately powered trial has yet shown that fat grafting prevents diabetic foot ulcers or recurrence. For now, plantar fat augmentation remains an emerging adjunct to, not a replacement for, established pressure-reduction strategies such as therapeutic footwear and offloading.

References

  • Bus SA, Sacco ICN, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3651.
  • Gusenoff JA, Mitchell RT, Jeong K, Wukich DK, Gusenoff BR. Autologous fat grafting for pedal fat pad atrophy: a prospective randomized clinical trial. Plastic and Reconstructive Surgery. 2016;138(5):1099–1108.
  • Gusenoff BF, Gusenoff JA. Can autologous fat grafting help address fat pad atrophy in patients with diabetes? Podiatry Today. 2016;29(5).
  • Sbitan L, Qandah A, Alzraikat N, Camargo CP. Adipose tissue and fat-derived products in wound, ulcer, and scar management: a systematic review. Frontiers in Surgery. 2025;12:1666776.
  • Ouyang H, Tang Y, Yang F, et al. Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review. Frontiers in Endocrinology. 2023;14:1256081.
  • Ashmore et al. A systematic review of submetatarsal fat pad augmentation for the treatment and prevention of diabetes-related foot ulceration. Journal of Foot and Ankle Research. 2025.

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.